142 related articles for article (PubMed ID: 15379942)
21. Is bleomycin necessary in adjuvant chemotherapy of clinical stage I non-seminomatous testicular cancer?
Mezvrishvili Z; Managadze L
Georgian Med News; 2006 May; (134):25-8. PubMed ID: 16783058
[TBL] [Abstract][Full Text] [Related]
22. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.
Kesler KA; Rieger KM; Hammoud ZT; Kruter LE; Perkins SM; Turrentine MW; Schneider BP; Einhorn LH; Brown JW
Ann Thorac Surg; 2008 Feb; 85(2):371-8. PubMed ID: 18222228
[TBL] [Abstract][Full Text] [Related]
23. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
24. Optimal treatment strategy for intracranial germ cell tumors: a single institution analysis.
Kanamori M; Kumabe T; Saito R; Yamashita Y; Sonoda Y; Ariga H; Takai Y; Tominaga T
J Neurosurg Pediatr; 2009 Dec; 4(6):506-14. PubMed ID: 19951035
[TBL] [Abstract][Full Text] [Related]
25. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
[TBL] [Abstract][Full Text] [Related]
26. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
27. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.
Shintaku I; Satoh M; Okajima E; Fujimoto H; Kamoto T; Ogawa O; Kawai K; Akaza H; Tsukamoto T; Naito S; Miki T; Arai Y
Jpn J Clin Oncol; 2008 Apr; 38(4):281-7. PubMed ID: 18321891
[TBL] [Abstract][Full Text] [Related]
28. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.
Aparicio J; Germà JR; García del Muro X; Maroto P; Arranz JA; Sáenz A; Barnadas A; Dorca J; Gumà J; Olmos D; Bastús R; Carles J; Almenar D; Sánchez M; Paz-Ares L; Satrústegui JJ; Mellado B; Balil A; López-Brea M; Sánchez A;
J Clin Oncol; 2005 Dec; 23(34):8717-23. PubMed ID: 16260698
[TBL] [Abstract][Full Text] [Related]
29. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
30. During twenty years of Cisplatin-based therapy the face of nonseminomatous testicular germ cell tumors is still changing: an evaluation of presentation, management, predictive factors and survival.
Heinzelbecker J; Katzmarzik M; Weiss C; Trojan L; Haecker A
Int Braz J Urol; 2013; 39(1):10-21. PubMed ID: 23489512
[TBL] [Abstract][Full Text] [Related]
31. Testicular germ cell tumors in prepubertal children.
Kusumakumary P; Mathew BS; Hariharan S; Priyakumari T; Rajan B
Pediatr Hematol Oncol; 2000; 17(1):105-11. PubMed ID: 10689721
[TBL] [Abstract][Full Text] [Related]
32. Current management of stage I testicular non-seminomatous germ cell tumours.
Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
[TBL] [Abstract][Full Text] [Related]
33. Improvement in the outcome of children with germ cell tumors.
Lopes LF; Sonaglio V; Ribeiro KC; Schneider DT; de Camargo B
Pediatr Blood Cancer; 2008 Feb; 50(2):250-3. PubMed ID: 17554793
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
35. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.
Ronnen EA; Kondagunta GV; Bacik J; Marion S; Bajorin DF; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Oct; 23(28):6999-7004. PubMed ID: 16192587
[TBL] [Abstract][Full Text] [Related]
36. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
37. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure.
Geldart TR; Gale J; McKendrick J; Kirby J; Mead G
BJU Int; 2006 Aug; 98(2):353-8. PubMed ID: 16879677
[TBL] [Abstract][Full Text] [Related]
38. Short- and long-term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy.
Andrade RS; Kesler KA; Wilson JL; Brooks JA; Reichwage BD; Rieger KM; Einhorn LH; Brown JW
Ann Thorac Surg; 2004 Oct; 78(4):1224-8; discussion 1228-9. PubMed ID: 15464475
[TBL] [Abstract][Full Text] [Related]
39. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
[TBL] [Abstract][Full Text] [Related]
40. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]